Malaria Drug Helps Coronavirus Patients Improve, in Small Study

A group of moderately ill people were given hydroxychloroquine, which appeared to ease their symptoms quickly, but more research is needed.
Source: NYT - Category: American Health Authors: Tags: Coronavirus (2019-nCoV) Hydroxychloroquine (Drug) Drugs (Pharmaceuticals) Quarantines Shortages Autoimmune Diseases Pneumonia Immune System Malaria Schaffner, William your-feed-healthcare Source Type: news

Related Links:

Publication date: Available online 2 June 2020Source: Life SciencesAuthor(s): Fereshteh Yazdanpanah, Michael R. Hamblin, Nima Rezaei
Source: Life Sciences - Category: Biology Source Type: research
Publication date: 1 September 2020Source: Life Sciences, Volume 256Author(s): Fedor Simko, Russel J. Reiter
Source: Life Sciences - Category: Biology Source Type: research
Authors: Frost DW, Shah R, Melvin L, Galán de Juana M, MacMillan TE, Abdelhalim T, Lai A, Rawal S, Cavalcanti RB PMID: 32493744 [PubMed - as supplied by publisher]
Source: Canadian Medical Association Journal - Category: General Medicine Tags: CMAJ Source Type: research
Authors: Mishra S, Kwong JC, Chan AK, Baral SD PMID: 32493741 [PubMed - as supplied by publisher]
Source: Canadian Medical Association Journal - Category: General Medicine Tags: CMAJ Source Type: research
Authors: Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, He N, Wu Z, Zhang Q, Gong X, Tang Q, Du X, Ying Y, Xu X, Zhang Y, Liu J, Li Y, Shen N, Couban RJ, Ibrahim QI, Guyatt G, Zhai S Abstract BACKGROUND: Antiviral medications are being given empirically to some patients with coronavirus disease 2019 (COVID-19). To support the development of a COVID-19 management guideline, we conducted a systematic review that addressed the benefits and harms of 7 antiviral treatments for COVID-19. METHODS: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PubMed and 3 Chinese databases (CNKI, WA...
Source: Canadian Medical Association Journal - Category: General Medicine Tags: CMAJ Source Type: research
Publication date: Available online 4 June 2020Source: Polymer Degradation and StabilityAuthor(s): Mathew Celina, Estevan Martinez, Michael A. Omana, Andres Sanchez, Dora Wiemann, Matthew Tezak, Tim R. Dargaville
Source: Polymer Degradation and Stability - Category: Chemistry Source Type: research
Sweden seesthird consecutive day of over 1,000 new cases; virus ‘under control ’ in France; Brazil death toll passes Italy; New York urges protesters to get testedWHO changes advice to back medical-grade masks for over-60sEU pledges to lift internal border controls by end of monthThe first wave of Covid-19 is not over – but how might a second look?Coronavirus lates: at a glanceSee all our coronavirus coverage8.01pmBSTEstoniahas developed an app that could serve as a digital “immunity passport”, allowing users with antibodies to show employers and others their reduced risk of spreading coronavi...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak World news Science Infectious diseases Australia news UK news US news Microbiology Medical research Source Type: news
CONCLUSION: For better therapeutic outcome, proper selection of drug moiety with its appropriate administration is the major requisite. With the advent of nanotechnology, the development of nanocarrier for dermatologic application has been successfully demonstrated in positioning the systemically administrated drug into topical targeted delivery. In a nutshell, to achieve successful treatment strategies towards psoriasis, there is a need to focus on the development of stable, non-toxic nanocarrier for topical delivery. Inclusion of the existing orally administered drug moiety into nanocarriers for topical delivery is propo...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide. A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Explainer Source Type: news
More News: American Health | Autoimmune Disease | Coronavirus | COVID-19 | Hydroxychloroquine | Malaria | Pneumonia | Study